■这项研究的目的是评估托福列净的效果,一种选择性钠-葡萄糖协同转运蛋白2抑制剂,关于肝酶的循环水平,2型糖尿病(T2DM)患者的尿酸和血红蛋白水平。
■我们评估了循环天冬氨酸氨基转移酶(AST)的纵向变化,丙氨酸氨基转移酶(ALT),γ-谷氨酰转肽酶(γ-GTP),尿酸,使用UTOPIA试验获得的数据,Tofogliflozin(n=169)和常规治疗组(n=170)的血红蛋白水平,一项随机前瞻性研究旨在评价托福列净预防动脉粥样硬化的疗效.
■在104周内,托福列净治疗,但不是常规治疗,显著降低AST,ALT,和γ-GTP水平。tofogliflozin组的这种减少明显大于常规组。分层分析表明,肥胖患者(定义为体重指数(BMI)≥25.0kg/m2),在AST中观察到显著差异,ALT,治疗组之间从基线到104周的γ-GTP变化。然而,在没有肥胖的患者中,从基线到104周,治疗组之间的AST和γ-GTP变化无显著差异.多因素回归分析显示,BMI和HbA1c水平的变化与AST的变化独立相关。ALT,和γ-GTP水平。与常规组相比,托福列净组从基线到104周的尿酸降低和血红蛋白增加明显更大。
■托福列净对循环肝酶水平的有益作用,尿酸,2型糖尿病患者Hb持续2年。
■UMIN000017607(https://www.乌明。AC.jp/icdr/index。html).
■在线版本包含补充材料,可在10.1007/s13340-024-00693-x获得。
UNASSIGNED: The aim of the study was to evaluate the effects of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on circulating levels of hepatic enzymes, uric acid and hemoglobin levels in patients with type 2 diabetes mellitus (T2DM).
UNASSIGNED: We evaluated longitudinal changes in circulating aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid, and hemoglobin levels in tofogliflozin (n = 169) and conventional treatment groups (n = 170) using data obtained from the UTOPIA trial, a randomized prospective study conducted to evaluate the efficacy of tofogliflozin in preventing atherosclerosis.
UNASSIGNED: Within 104 weeks, tofogliflozin treatment, but not conventional treatment, significantly reduced AST, ALT, and γ-GTP levels. This reduction was significantly greater in the tofogliflozin group than in the conventional group. Stratified analysis showed that, in patients with obesity (defined as body mass index (BMI) ≥ 25.0 kg/m2), significant differences were observed in AST, ALT, and γ-GTP changes from baseline to 104 weeks between treatment groups. However, in patients without obesity, there were no significant differences in AST and γ-GTP changes from baseline to 104 weeks between treatment groups. Multivariable regression analysis showed that changes in BMI and HbA1c levels were independently associated with changes in AST, ALT, and γ-GTP levels. The reduction of uric acid and the increase of hemoglobin from baseline to 104 weeks were significantly greater in the tofogliflozin group than in the conventional group.
UNASSIGNED: The beneficial effects of tofogliflozin on circulating levels of hepatic enzymes, uric acid, and Hb lasted for 2 years in patients with T2DM.
UNASSIGNED: UMIN000017607 (https://www.umin.ac.jp/icdr/index.html).
UNASSIGNED: The online version contains supplementary material available at 10.1007/s13340-024-00693-x.